Born to Heal: The Hidden Power of Placental Stem Cells

Recent scientific advances have highlighted the human placenta, particularly the chorion, as a valuable source of stem cells with broad therapeutic potential. Traditionally discarded after childbirth, the placenta is now being explored as a rich, ethically uncomplicated reservoir of multipotent and pluripotent cells—offering opportunities for both autologous and allogeneic regenerative therapies.

The Science Behind Placental Stem Cells

The placenta, formed during early gestation (~12 days post-conception), comprises both fetal (chorion and amnion) and maternal components. It plays a critical role in nutrient transfer, hormone production, and immune tolerance during pregnancy.

Types of Stem Cells in the Placenta

The placenta harbors multiple stem cell types, including:

1. Amniotic Epithelial (AE) Cells – Derived from the epiblast, these exhibit differentiation potential into all three germ layers without forming teratomas.

2. Mesenchymal Stem Cells (MSCs) – Found in both the amniotic membrane and the chorion. These are multipotent, capable of differentiating into bone, cartilage, and adipose tissue, and are notable for their immunomodulatory properties.

3. Hematopoietic Stem Cells (HSCs) – Present in the chorionic plate and placental blood, HSCs contribute to hematopoiesis and immune system regulation.

Ethical and Clinical Advantages

Unlike embryonic stem cells, placental stem cells are obtained postnatally, eliminating major ethical concerns. Studies have shown that placentas may yield more stem cells than cord blood, making them a plentiful and practical alternative for therapeutic banking.

Immunological Properties

One of the most compelling advantages of placental stem cells is their low immunogenicity. They express low levels of MHC class II molecules and secrete anti-inflammatory cytokines, which may reduce graft-versus-host responses. This makes them well-suited for allogeneic transplant settings, including in patients who are not matched siblings or relatives.

Regenerative Potential and Future Directions

Placental stem cells show promise in the treatment of:

• Autoimmune diseases (e.g., multiple sclerosis, lupus)

• Tissue damage (e.g., cartilage or neural injuries)

• Metabolic disorders (e.g., diabetes)

• Neurodegenerative conditions

Much of their healing effect is thought to arise from paracrine activity—the release of exosomes, cytokines, and growth factors that stimulate local tissue repair and immunomodulation .

Clinical Implications and Strategic Banking

Strategic collection and preservation of placental tissue could create biological insurance for newborns and potentially their family members. Banking systems that preserve not only cord blood but also chorionic and amniotic stem cells may significantly expand therapeutic options in the future.

References

1. Maltepe E, Fisher SJ. Placenta: the forgotten organ. Annu Rev Cell Dev Biol. 2015;31:523–552.

2. Miki T, et al. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005;23(10):1549–1559.

3. Parolini O, et al. Isolation and characterization of mesenchymal stem cells from human amniotic membrane. Curr Protoc Stem Cell Biol. 2008.

4. Barcena A, et al. The human placenta is a hematopoietic organ during the embryonic and fetal periods of development. Dev Biol. 2009;327(1):24–33.

5. In 't Anker PS, et al. Amniotic fluid as a novel source of mesenchymal stem cells. Stem Cells. 2003;21(6):687–691.

6. Portmann-Lanz CB, et al. Immunological properties of placental-derived stem cells. Am J Obstet Gynecol. 2006;194(3):e22–e29.

7. Silini AR, et al. Paracrine mechanisms of mesenchymal stem/stromal cells: biological and clinical relevance. Stem Cells Transl Med. 2017;6(12):2383–2394.